Immuron Ltd (IMRN) Actualités

Immuron requests pre-IND meeting for IMM-529 with FDA filing

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron CEO Steven Lydeamore to present at Peak Sky High

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an...

Immuron Director Resignation

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an...

Immuron to host Live Virtual Event

MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an...

Immuron Travelan® sales continued strong growth

Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron Presentation Australian Biologics Festival 2024

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immuron achieves record Travelan® sales

Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5...